Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
The stock options have an exercise price of $15.49 per share, which is equal to the closing price of Alector’s common stock on the grant date. The inducement stock options vest monthly over 48 months in equal monthly amounts subject to Dr. Grasso’s continued employment with the Company.
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South
Argot Partners (investors)
Source: Alector, Inc.